Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 3, 1998, Pages 298-305

  Andreasen, N ^a,c   Vanmechelen, E ^b   Van De Voorde, A ^b   Davidsson, P ^d   Hesse, C ^d   Tarvonen, S ^e   Raiha I ^e   Sourander, L ^e   Winblad, B ^c   Blennow, K ^d  

^a River Valley Hospital   (Sweden)

^b INNOGENETICS   (Belgium)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Alzheimer's disease; Biochemical markers; Cerebrospinal fluid; Tau protein

Indexed keywords

BIOCHEMICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; NORMAL HUMAN; PRIORITY JOURNAL; SWEDEN;

EID: 0031947586     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.3.298     Document Type: Article

References (45)

1. McKhann G, Drachman D, Folstein M, et at. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
2. Coleman PD, Flood DG. Neuron numbers and dendrite extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987;8:521-15.
3. Blennow K, Bogdanovic N, Alafuzoff I, et al. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm Park Dis Dement Sect 1996;103:603-18.
4. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. TINS 1993;16:460-5.
5. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
6. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-52.
7. Blennow K, Wallin A, Ågren H, et al Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26: 231-45.
8. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995;186:189-91.
9. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38: 643-8.
10. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788-93.
11. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995;59: 280-3.
12. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995;186:181-3.
13. Skoog I, Vanmechelen E, Andreasson LA, et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 1995;4:433-42.
14. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512-8.
15. Munroe WA, Southwick PC, Chang L, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 1995;25:207-17.
16. Hock C, Golombowski S, Naser W, et al. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol 1995;37:414-5.
17. Riemenschneider M, Buch K, Schmolke M, et al. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996;212:209-11.
18. Rösler N, Wichart I, Jellinger KA. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;60: 237-8.
19. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632-5.
20. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
21. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342: 697-9.
22. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43: 1467-72.
23. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimers disease. Proc Natl Acad Sci USA 1993;90:1977-81.
24. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filaments formation in the Alzheimers disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125: 163-71.
25. Han SH, Hulette C, Saunders AM, et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and age-matched controls. Exp Neurol 1994;128:13-26.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: APA, 1987.
27. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:243-5.
28. Folstein M, Folstein S, McHugh P. "Mini-mental state" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
29. Tarvonen-Schröoder S, Räihä I, Kurki T, et al. Clinical characteristics of rapidly progressive leuko-araiosis. Acta Neurol Scand 1995;91:399-404.
30. Kane JW, Gowland G. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem 1986;23:509-13.
31. Altman DG, Gore SM, Gardner MJ, et al. Statistical guidelines for contributors to medical journals. BMJ 1983;286: 1489-93.
32. Wallin A, Blennow K. The pathogenetic basis of vascular dementia. Alzheimer Dis Assoc Disord 1991;5:91-102.
33. Jellinger KA. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol 1996;91:219-20.
34. Kosunen O, Soininen H, Paljärvi L, et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol 1996;91:185-93.
35. Kakulas BA, Wilton SD, Fabian VA, et al. Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet 1996;348:483.
36. Saunders AM, Hulette O, Welsh-Bohmer KA, et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 1996; 348:90-3.
37. Smith AD, Jobst KA, Johnston C, et al. Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet 1996;348:483-4
38. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59.
39. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42: 631-9.
40. Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541: 163-6.
41. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-8.
42. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913-7.
43. Ihara Y, Nukina N, Miura R, et al. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 1986;99:1807-10.
44. 262 phosphorylation. Neurosci Lett 1995;192:209-12.
45. Richey PL, Siedlak SL, Smith MA, et al. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem Biophys Res Comm 1995;208:657-63.